| Literature DB >> 29151531 |
Seizaburo Masuda1, Masanori Murakami1, Ryotaro Bouchi1, Isao Minami1, Koshi Hashimoto1,2, Takanobu Yoshimoto1, Yoshihiro Ogawa1.
Abstract
We herein report a case of a 20-year-old woman who experienced hypoglycemia in parallel with acute weight loss confirmed by continuous glucose motoring (CGM). When she recovered from the acute weight loss, CGM revealed nocturnal and postprandial hypoglycemia. Six months were required to resolve the hypoglycemia and hyperinsulinemia after the recovery of her weight. Our case suggests that the adaption of insulin secretion to the rapid loss of weight and to the recovery of weight may require a long period of time, leading to the excessive secretion of insulin relative to the glucose level and repeated hypoglycemic episodes with postprandial hyperinsulinemia.Entities:
Keywords: CGM; hypoglycemia; weight loss
Mesh:
Year: 2017 PMID: 29151531 PMCID: PMC5874342 DOI: 10.2169/internalmedicine.9452-17
Source DB: PubMed Journal: Intern Med ISSN: 0918-2918 Impact factor: 1.271
Figure 1.The course of body weight from July 2015 to August 2016.
Laboratory Data on the First Admission.
| Complete Blood count | ||
|---|---|---|
| White blood cell | 5,600 | /µL |
| Total lymphocyte | 1,064 | /µL |
| Red blood cell | 439×104 | /µL |
| Hemoglobin | 13.9 | g/dL |
| Hematocrit | 37.2 | % |
| Platelet | 21.8×104 | /µL |
| Bloood Chemistry | ||
| Total protein | 7.2 | g/dL |
| Albumin | 4.7 | g/dL |
| Sodium | 139 | mEq/L |
| Potassium | 3.9 | mEq/L |
| Chlorine | 102 | mEq/L |
| Triglycerides | 50 | mg/dL |
| HDL-Chol | 63 | mg/dL |
| LDL-Chol | 92 | mg/dL |
| Glucose | 67 | mg/dL |
| HbA1c(NGSP) | 4 | % |
| Endocrinological data | ||
| IRI | 4 | μU/mL |
| Insulin antibody | <0.4 | U/mL |
| IRG | 115 | pg/mL |
| GH | 3.58 | ng/mL |
| IGF-1 | 295 | ng/mL |
| Adrenaline | 0.02 | pg/mL |
| Noradrenaline | 0.17 | pg/mL |
| Dopamine | 0.02 | pg/mL |
| ACTH | 13.6 | pg/mL |
| Cortisol | 10.5 | µg/dL |
| TSH | 1.67 | µIU/mL |
| FT3 | 2.82 | pg/mL |
| FT4 | 1 | ng/dL |
HDL-Chol: high density lipoprotein cholesterol, LDL-Chol: low density lipoprotein, HbA1c: hemoglobin A1c, IRI: immunoreactive insulin, IRG: immunoreactive glucagon, GH: growth hormone, IGF-1: insulin-like growth factor 1, ACTH: adrenocorticotropic hormone, TSH: thyroid stimulating hormone, FT3: free triiodothyronine, FT4: free thyroxine
Figure 2.A: A 75-g gram oral glucose tolerance test given at the first admission. The plasma glucose (■) and serum IRI (○) concentrations were measured at 0, 30, 60, 90, 120, 180 and 240 minutes after glucose load. The area under the curve of IRI (AUC) from 0 to 180 minutes was calculated. B: A 75-g gram oral glucose tolerance test given at the second admission. The plasma glucose (■) and serum IRI (○) concentrations were measured at 0, 30, 60, 90, 120 and 180 minutes after glucose load. The area under the curve of IRI (AUC) from 0 to 180 minutes was calculated.
Figure 3.The result of continuous glucose monitoring system at the first (A) and second admission (B). The minimum glucose level and total time of hypoglycemia are shown.